ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

Zacks11-19

Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484920578?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4qYAeIby_0fxQYGokmloZw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1","is_english":true,"pubTime":"2024-11-19 23:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484920578","market":"us","top_or_hot":-1,"title":"ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap","media":"Zacks","content":"<div>\n<p>Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the...</p>\n\n<a href=\"https://finance.yahoo.com/news/aldx-fda-accepts-resubmitted-nda-150000461.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/aldx-fda-accepts-resubmitted-nda-150000461.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the...</p>\n\n<a href=\"https://finance.yahoo.com/news/aldx-fda-accepts-resubmitted-nda-150000461.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0122379950.USD","symbol_name":"贝莱德世界健康科学A2","start_time":0,"source_url":"https://finance.yahoo.com/news/aldx-fda-accepts-resubmitted-nda-150000461.html","article_id":"2484920578","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4qYAeIby_0fxQYGokmloZw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484920578","pubTimestamp":1732028400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application  for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the signs and symptoms of dry eye disease.With the FDA accepting the resubmitted NDA for review, a decision from the regulatory body is expected on April 2, 2025.Simultaneously, Aldeyra announced that it has expanded its existing option agreement with AbbVie ABBV.Shares of Aldeyra were up 11.6% on Nov. 18 following the announcement of the news. The stock has rallied 33.9% so far this year against the industry’s decline of 6%.If ABBV chooses to exercise the option, ALDX will be eligible to receive an upfront payment of $100 million less option fees of $6 million, which was previously paid. Additionally, Aldeyra is eligible to receive up to $300 million in regulatory and commercial milestone payments from AbbVie, including a $100 million","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0122379950.USD":"贝莱德世界健康科学A2","CSTL":"Castle Biosciences, Inc.","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IMCR":"Immunocore Holdings plc","CRL":"查尔斯河","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","ALDX":"Aldeyra Therapeutics Inc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","ABBV":"艾伯维公司","BK4196":"保健护理服务","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4121":"生命科学工具和服务","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4588":"碎股","LU0882574055.USD":"富达全球健康医疗A ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4581":"高盛持仓"},"translate_title":"FDA接受眼科药物Reproxalap重新提交的NDA，ALDX上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":1,"CRL":1,"CSTL":1,"IMCR":1,"ABBV":0.9},"content_text":"Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the signs and symptoms of dry eye disease.\nWith the FDA accepting the resubmitted NDA for review, a decision from the regulatory body is expected on April 2, 2025.\nSimultaneously, Aldeyra announced that it has expanded its existing option agreement with AbbVie ABBV.\nShares of Aldeyra were up 11.6% on Nov. 18 following the announcement of the news. The stock has rallied 33.9% so far this year against the industry’s decline of 6%.\nImage Source: Zacks Investment Research\nMore on ALDX's NDA Resubmission of Reproxalap\nWe remind investors that in November 2023, Aldeyra received a complete response letter (CRL) from the FDA for its NDA of reproxalap to treat dry eye disease. Per the FDA, the study results supporting the NDA failed to demonstrate reproxalap’s efficacy in treating ocular symptoms associated with dry eyes, which formed the basis of the CRL issue.\nBack then, the FDA had recommended that at least one additional adequate and well-controlled study should be conducted on reproxalap to demonstrate a positive effect on the treatment of ocular symptoms of dry eye.\nFollowing this, Aldeyra decided to initiate a dry eye chamber clinical study to address the issues stated by the FDA in the CRL.\nIn May, ALDX enrolled the first patient in a phase III dry eye chamber study, which was designed to ensure a potential resubmission of NDA for reproxalap for treating dry eye disease.\nIn August, the company announced that the phase III dry eye chamber study, which evaluated reproxalap for the treatment of dry eye disease met the primary endpoint. In the study, treatment with reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, an FDA-accepted symptom of dry eye disease.\nAldeyra resubmitted the NDA for reproxalap for treating signs and symptoms of dry eye disease last month.\nALDX's Option Agreement With AbbVie\nUnder the latest expanded option agreement, Aldeyra will begin certain pre-commercial activities, for which 40% will be paid by the company, and the remaining 60% will be borne by ABBV if the option is exercised. AbbVie too has independently started pre-commercial planning activities.\nWe remind investors that, in October 2023, Aldeyra entered into an exclusive option agreement with AbbVie, which granted the latter an option to acquire a co-exclusive license to develop, manufacture and commercialize reproxalap within the United States and an exclusive license for the same outside the United States.\nIf ABBV chooses to exercise the option, ALDX will be eligible to receive an upfront payment of $100 million less option fees of $6 million, which was previously paid. Additionally, Aldeyra is eligible to receive up to $300 million in regulatory and commercial milestone payments from AbbVie, including a $100 million milestone payment payable upon the potential FDA approval for reproxalap.\nAldeyra and AbbVie will share U.S. profits and losses received in connection with the commercialization of reproxalap. While Aldeyra would receive 40% of the profits, ABBV would receive the remaining 60%.\nALDX's Zacks Rank & Key Picks\nAldeyra currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR and Castle Biosciences, Inc. CSTL, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 54.6%.\nIMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 29.3%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\nAldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nImmunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484920578"}